Company Performance Metrics

- Robert Thomas Keenan: Chief Medical Officer
- Stephen Smolinski: Chief Business OfficerPast Role: Swedish Orphan Biovitrum, Global Head
Arthrosi Therapeutics develops pharmaceutical treatments centered on gout and related conditions through clinical research and drug development programs. The company advances its investigational oral therapy designed to lower uric acid, address gout flares, and reduce hard crystal deposits in joint tissue by progressing it through late-stage
clinical studies. Its work includes conducting randomized controlled trials to gather data on the therapeutic effects and safety profile of its lead compound in diverse patient groups. Arthrosi Therapeutics also engages in regulatory and scientific activities to support potential future approvals and collaborations. The organization communicates progress through published trial milestones and industry announcements.